TITLE

Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

PUB. DATE
November 2006
SOURCE
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study determining the efficacy of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The study involved randomized placebo-controlled trials in which 10,101 postmenopausal women with increased risk for coronary heart disease were administered oral raloxifene for a follow-up period of 5.6 years. The study concluded that, raloxifene reduced risk for invasive breast cancer in these women but did not affect risk for cardiovascular diseases.
ACCESSION #
23245706

 

Related Articles

  • Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p72 

    The article focuses on a study finding the efficacy of tamoxifen and raloxifene for preventing invasive breast cancer in women at increased risk. The study involved randomized controlled trials, in which many postmenopausal women were administered tamoxifen and raloxifene for a period of 3.9...

  • PEARL: High-dose lasofoxifene reduced risk for fracture, breast cancer, coronary events. Southall, Jennifer // Endocrine Today;Mar2010, Vol. 8 Issue 3, p28 

    The article reports on the decrease in risks for both vertebral and nonvertebral fractures, estrogen receptor-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis who received once-daily lasofoxifene, according to the Postmenopausal Evaluation and...

  • Bayer and Onyx report positive results from Phase II breast cancer trial.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p16 

    The article reports on the results from a randomized Phase II breast cancer trial sponsored by the Northwestern University in Evanston, Illinois. The study evaluates Nexavar tablets in combination with the chemotherapeutic agent, paclitaxel, in breast cancer patients. Bayer HealthCare and Onyx...

  • Gender Balance in Cardiovascular Research. Dougherty, Anne Hamilton // Texas Heart Institute Journal;2011, Vol. 38 Issue 2, p148 

    The article discusses the need for gender-balanced study population in cardiovascular disease (CVD). It states that most clinical trials for CVD involve a population which is 85 percent male, with female participation usually limited to those who are postmenopausal. Women were not given the...

  • Chemoprevention of Breast Cancer: Recommendations and Rationale: U.S. Preventive Services Task Force. Berg, Alfred O. // Internet Journal of Oncology;2002, Vol. 1 Issue 2, p1 

    The article presents information on the recommendations by the U.S. Preventive Services Task Force (USPSTF) on the increasing rate of breast cancer in women. According to USPSTF, tamoxifen and raloxifene can prevent the risk of breast cancer in women. It states that from the randomized...

  • Treatment - Prevention.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 1, p35 

    The article discusses the effectiveness and safety of tamoxifen, raloxifene and tribolone in decreasing the threat of primary breast cancer among women by sub-group through age, family record of breast cancer and menopausal condition. It states that the study contains double-blind,...

  • Chemoprevention of Breast Cancer: Recommendations and Rationale: U.S. Preventive Services Task Force. Berg, Alfred O. // Internet Journal of Oncology;2002, Vol. 1 Issue 2, p1 

    The article presents information on the recommendations by the U.S. Preventive Services Task Force (USPSTF) on the increasing rate of breast cancer in women. According to USPSTF, tamoxifen and raloxifene can prevent the risk of breast cancer in women. It states that from the randomized...

  • 'Think Pink' awareness much higher than threat. Andruss, Paula // Marketing News;2/15/2006, Vol. 40 Issue 3, p14 

    The article focuses on the need for women to increase awareness of their risk of having heart disease. It explains why breast cancer programs overshadow the promotion of and dissemination of information about heart disease. It offers information on the impact of politics on the popularity of the...

  • ESMO 2009: findings confirm adjuvant use of aromatase inhibitors in early breast cancer.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p10 

    The article reports on the results of the randomized Phase III tamoxifen exemestane adjuvant multinational (TEAM) study which suggest that Aromasin is superior to tamoxifen in the treatment of early-stage breast cancer. In comparison with tamoxifen, Aromasin is associated with improved...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics